Hemab Therapeutics (NASDAQ:COAG) Hits New 1-Year High - Time to Buy?

Key Points

• Hemab Therapeutics reached a new 52-week high of $52.29, closing its latest session at $51.07 and giving the company a market capitalization of approximately $2.37 billion.
• Analyst sentiment is broadly positive: five analysts rate the stock “Buy” and one rates it “Hold,” producing a “Moderate Buy” consensus and an average price target of $48.00—below the current share price.
• Insiders have been buying shares, including a 61,523-share purchase by major shareholder RA Capital Management; however, Hemab remains a clinical-stage biotech that reported a quarterly loss of $23.98 per share.

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $52.29 and last traded at $51.07, with a volume of 38258 shares. The stock had previously closed at $50.09.

Analyst Ratings Changes

A number of research analysts recently commented on COAG shares. Zacks Research upgraded Hemab Therapeutics to a "hold" rating in a report on Wednesday, May 27th. Jefferies Financial Group upped their price target on Hemab Therapeutics from $39.00 to $47.00 and gave the company a "buy" rating in a research note on Monday, July 13th. The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a "buy" rating and a $36.00 target price for the company. Evercore began coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued an "outperform" rating and a $50.00 target price for the company. Finally, HC Wainwright raised their price objective on shares of Hemab Therapeutics from $40.00 to $52.00 and gave the company a "buy" rating in a research note on Monday, July 13th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $48.00.

Hemab Therapeutics Price Performance

The firm has a market capitalization of $2.37 billion and a PE ratio of -2.11. The business's fifty day moving average is $35.62.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last issued its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Insider Activity at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. bought 61,523 shares of the business's stock in a transaction dated Tuesday, June 16th. The shares were acquired at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the transaction, the insider owned 6,444,637 shares of the company's stock, valued at approximately $160,987,032.26. This trade represents a 0.96% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders bought a total of 120,206 shares of company stock worth $2,994,826 in the last 90 days.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company's research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab's pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source